Menu
About Us
Company Overview
Corporate Culture
Manufacturing Base
MAH
Drug Development to Commercialization
Milestones
Code of Business Ethics
Services
Services
Providing reliable CDMO solutions with excellent quality and professional services
ADC Platform
Overview
ADC R&D Service Platform
Conjugation Process
Development
and Optimization
Drug Product
Formulation and
Lyophilization Process
Analysis Services
Antibody Manufacturing
ADC Drug Substance
Manufacturing
Lyophilized Drug
Product Manufacture
Process and Analytical Method Development
Overview
Cell Culture
Process Development
Purification Process
Development
Drug Product
Formulation and
Lophilization Process
Analysis Services
GMP Manufacturing
Overview
Drug Substance
Manufacturing
Drug Product
Manufacturing
Process Characterization
/Process Validation
Technology Transfer
Overview
Technology Transfer
Quality
Overview
Quality Control
Quality Assurance
Regulatory Affairs
Overview
Service and Advantages
Investor Relations
Company Profile
Corporate Governance
Announcements and Circulars
The Listed Files
Financial Reports and ESG Reports
Company Promotion Materials
Investor Relations Query
Investor Relations Journal
News & Events
News
Events
Media Attention
Partner News
Resources
Technical Articles
Download Center
Join Us
Members of TOT
Join in TOT
Contact Us
EN
繁體
简体
EN
繁體
简体
Home
<
News & Events
News & Events
News
Events
Media Attention
Partner News
2023
2020
2021
2022
2023
2024
2023.07
05
TOT Biopharm entered into strategic cooperation with GlycanLink on Glycol-site specific ADC technology
TOT Biopharm and GlycanLink jointly announced in-depth strategic cooperation on DisacLinkTM technology, for which GlycanLink owns proprietary intellectual property rights. With this cooperation, both parties will carry out joint technical research, jointl
2023.05
22
TOT BIOPHARM announces All-round CDMO strategic cooperation with BioRay
On May 19, 2023, TOT BIOPHARM (stock code: 1875.HK) announced a strategic cooperation was established with BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as BioRay). Dr. Haibin Wang, CEO of BioRay, and Dr. Jun Liu, CEO of TOT BIOPHARM attended t
2023.04
26
Passing the certification on “Implementation of The Standard”, TOT BIOPHARM Spares No Effort to Protect IP of CDMO Clients
Each building of the standardization system furtherenhances protection for innovation Following the ISO27001 information securitymanagement system certification, TOT BIOPHARM (Stock code: 1875.HK) hasrecently received good news that the company has succes
2023.04
26
TOT BIOPHARM and Escugen Biotechnology achieved a long-term strategic collaboration to advance the development and commercialization of ADC drugs
On April 25, 2023, TOT BIOPHARM(1875.HK) and Shanghai Escugen BiotechnologyCo., Ltd. ("EscugenBiotechnology ") achieved anin-depth strategic collaboration for the development and production of antibody-drugconjugate (ADC) from late clinical sta
2023.04
24
TOT BIOPHARM and Smart Nuclide announced a strategic cooperation to accelerate the development of radionuclide drug conjugates
On April 22, 2023, the opening ceremony of the Class B Radioisotope Laboratory of Suzhou Smart Nuclide Biopharmaceutical Co., Ltd. (hereinafter referred to as Smart Nuclide) was held in the Innovation and Entrepreneurship Center of Liandong U Valley in Su
2023.04
03
TOT BIOPHARM’s Certified IT Management System Guarantees Security of Customer
What is the sense of security?More than that your things outperform other’s while you possess what others have no access to. It is about we have thought thoughtfully in advance about things that haven’t come to your mind yetWith the progress of digitali…
2023.03
24
TOT BIOPHARM Announces 2022 Annual Results
«
1
»
The module is under construction
map